LXEO NASDAQ
New York City, NY 10010
US
Lexeo Therapeutics, Inc. is a genetic medicine firm currently in the clinical development phase, dedicated to addressing both inherited and acquired medical conditions. Its robust pipeline features several gene therapy candidates. These include LX2006, an AAVrh10-based therapy aimed at treating cardiomyopathy linked to Friedreich's ataxia (FA); LX2020, another AAVrh10-based candidate targeting arrhythmogenic cardiomyopathy; LX2021, designed for DSP cardiomyopathy; and LX2022, which focuses on hypertrophic cardiomyopathy (HCM) stemming from TNNI3 mutations. Furthermore, Lexeo is advancing LX1001, an AAVrh10-based gene therapy, alongside LX1020 and LX1021, all intended for individuals homozygous for APOE4. Additionally, LX1004 is under development to treat CLN2 Batten disease. Established in 2017, the company's headquarters are located in New York, New York.
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Townsend Richard Nol | S-Sale | 25,947 | $4.48 | 2026-07-01 |
| Tamayo Louis Edward | S-Sale | 4,641 | $4.49 | 2026-07-01 |
| Otero Jose Manuel | S-Sale | 4,666 | $4.48 | 2026-07-01 |
| Bhalla Narinder Pal | S-Sale | 22,306 | $4.42 | 2026-07-01 |
| Townsend Richard Nol | A-Award | 67,000 | — | 2026-06-29 |